
TOPAMAX[®] (topiramate) Tablets TOPAMAX[®] (topiramate capsules) Sprinkle Capsules

DESCRIPTION

Topiramate is a sulfamate-substituted monosaccharide. TOPAMAX[®] (topiramate) Tablets are available as 25 mg, 50 mg, 100 mg, and 200 mg round tablets for oral administration. TOPAMAX[®] (topiramate capsules) Sprinkle Capsules are available as 15 mg and 25 mg sprinkle capsules for oral administration as whole capsules or opened and sprinkled onto soft food.

Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula $C_{12}H_{21}NO_8S$ and a molecular weight of 339.37. Topiramate is designated chemically as 2,3:4,5-Di-*O*-isopropylidene- β -D-fructopyranose sulfamate and has the following structural formula:



TOPAMAX[®] (topiramate) Tablets contain the following inactive ingredients: lactose monohydrate, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hypromellose, titanium dioxide, polyethylene glycol, synthetic iron oxide (50, 100 and 200 mg tablets) and polysorbate 80.

TOPAMAX[®] (topiramate capsules) Sprinkle Capsules contain topiramate coated beads in a hard gelatin capsule. The inactive ingredients are: sugar spheres (sucrose

and starch), povidone, cellulose acetate, gelatin, silicone dioxide, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink.

CLINICAL PHARMACOLOGY Mechanism of Action:

The precise mechanisms by which topiramate exerts its anticonvulsant and migraine prophylaxis effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy and migraine prophylaxis. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.

Pharmacodynamics:

Topiramate has anticonvulsant activity in rat and mouse maximal electroshock seizure (MES) tests. Topiramate is only weakly effective in blocking clonic seizures induced by the GABA_A receptor antagonist, pentylenetetrazole. Topiramate is also effective in rodent models of epilepsy, which include tonic and absence-like seizures in the spontaneous epileptic rat (SER) and tonic and clonic seizures induced in rats by kindling of the amygdala or by global ischemia.

Pharmacokinetics:

The sprinkle formulation is bioequivalent to the immediate release tablet formulation and, therefore, may be substituted as a therapeutic equivalent.

Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose. The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution. The bioavailability of topiramate is not affected by food.

The pharmacokinetics of topiramate are linear with dose proportional increases in plasma concentration over the dose range studied (200 to 800 mg/day). The mean plasma elimination half-life is 21 hours after single or multiple doses. Steady state is thus reached in about 4 days in patients with normal renal function. Topiramate is 15-41% bound to human plasma proteins over the blood concentration range of 0.5 - 250 μ g/mL. The fraction bound decreased as blood concentration increased.

Carbamazepine and phenytoin do not alter the binding of topiramate. Sodium valproate, at 500 ug/mL (a concentration 5-10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%. Topiramate does not influence the binding of sodium valproate.

Metabolism and Excretion:

Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose). Six metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose. The metabolites are formed via hydroxylation, hydrolysis, and glucuronidation. There is evidence of renal tubular reabsorption of topiramate. In rats, given probenecid to inhibit tubular reabsorption, along with topiramate, a significant increase in renal clearance of topiramate was observed. This interaction has not been evaluated in humans. Overall, oral plasma clearance (CL/F) is approximately 20 to 30 mL/min in humans following oral administration.

Pharmacokinetic Interactions (see also Drug Interactions):

Antiepileptic Drugs

Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effect of these interactions on mean plasma AUCs are summarized under **PRECAUTIONS** (Table 3).

Special Populations: Renal Impairment:

The clearance of topiramate was reduced by 42% in moderately renally impaired (creatinine clearance 30-69 mL/min/1.73m²) and by 54% in severely renally impaired subjects (creatinine clearance <30 mL/min/1.73m²) compared to normal renal function subjects (creatinine clearance >70 mL/min/1.73m²). Since topiramate is presumed to undergo significant tubular reabsorption, it is uncertain whether this experience can be generalized to all situations of renal impairment. It is conceivable that some forms of renal disease could differentially affect glomerular filtration rate and tubular reabsorption resulting in a clearance of topiramate not predicted by creatinine clearance. In general, however, use of one-half the usual starting and maintenance dose is recommended in patients with moderate or severe renal impairment (see **PRECAUTIONS: Adjustment of Dose in Renal Failure** and **DOSAGE AND ADMINISTRATION**).

Hemodialysis:

Topiramate is cleared by hemodialysis. Using a high efficiency, counterflow, single pass-dialysate hemodialysis procedure, topiramate dialysis clearance was 120 mL/min with blood flow through the dialyzer at 400 mL/min. This high clearance (compared to 20-30 mL/min total oral clearance in healthy adults) will remove a clinically significant amount of topiramate from the patient over the hemodialysis treatment period. Therefore, a supplemental dose may be required (see **DOSAGE AND ADMINISTRATION**).

Hepatic Impairment:

In hepatically impaired subjects, the clearance of topiramate may be decreased; the mechanism underlying the decrease is not well understood.

Age, Gender, and Race:

The pharmacokinetics of topiramate in elderly subjects (65-85 years of age, N=16) were evaluated in a controlled clinical study. The elderly subject population had reduced renal function [creatinine clearance (-20%)] compared to young adults. Following a single oral 100 mg dose, maximum plasma concentration for elderly and young adults was achieved at approximately 1-2 hours. Reflecting the primary renal elimination of topiramate, topiramate plasma and renal clearance were reduced 21% and 19%, respectively, in elderly subjects, compared to young adults. Similarly, topiramate half-life was longer (13%) in the elderly. Reduced topiramate clearance resulted in slightly higher maximum plasma concentration (23%) and AUC (25%) in elderly subjects than observed in young adults. Topiramate clearance is decreased in the elderly only to the extent that renal function is reduced. As recommended for all patients, dosage adjustment may be indicated in the elderly patient when impaired renal function (creatinine clearance rate $\leq 70 \text{ mL/min}/1.73 \text{ m}^2$) is evident. It may be useful to monitor renal function in the elderly patient (see Special Populations: Renal Impairment, PRECAUTIONS: Adjustment of Dose in Renal Failure and **DOSAGE AND ADMINISTRATION).**

Clearance of topiramate in adults was not affected by gender or race.

Pediatric Pharmacokinetics:

Pharmacokinetics of topiramate were evaluated in patients ages 4 to 17 years receiving one or two other antiepileptic drugs. Pharmacokinetic profiles were obtained after one week at doses of 1, 3, and 9 mg/kg/day. Clearance was independent of dose.

Pediatric patients have a 50% higher clearance and consequently shorter elimination half-life than adults. Consequently, the plasma concentration for the same mg/kg dose may be lower in pediatric patients compared to adults. As in adults, hepatic enzyme-inducing antiepileptic drugs decrease the steady state plasma concentrations of topiramate.

CLINICAL STUDIES

The studies described in the following sections were conducted using TOPAMAX[®] (topiramate) Tablets.

Epilepsy

Monotherapy Controlled Trial

The effectiveness of topiramate as initial monotherapy in adults and children 10 years of age and older with partial onset or primary generalized seizures was established in a multicenter, randomized, double-blind, parallel-group trial.

The trial was conducted in 487 patients diagnosed with epilepsy (6 to 83 years of age) who had 1 or 2 well-documented seizures during the 3-month retrospective baseline phase who then entered the study and received topiramate 25 mg/day for 7 days in an open-label fashion. Forty-nine percent of subjects had no prior AED treatment and 17% had a diagnosis of epilepsy for greater than 24 months. Any AED therapy used for temporary or emergency purposes was discontinued prior to randomization. In the double-blind phase, 470 patients were randomized to titrate up to 50 mg/day or 400 mg/day. If the target dose could not be achieved, patients were maintained on the maximum tolerated dose. Fifty eight percent of patients achieved the maximal dose of 400 mg/day for > 2 weeks, and patients who did not tolerate 150 mg/day were discontinued. The primary efficacy assessment was a between group comparison of time to first seizure during the double-blind phase. Comparison of the Kaplan-Meier survival curves of time to first seizure favored the topiramate 400 mg/day group over the topiramate 50 mg/day group (p=0.0002, log rank test; Figure 1). The treatment effects with respect to time to first seizure were consistent across various patient subgroups defined by age, sex, geographic region, baseline body weight, baseline seizure type, time since diagnosis, and baseline AED use.




Figure 1: Kaplan-Meier Estimates of Cumulative Rates for Time to First Seizure

Adjunctive Therapy Controlled Trials in Adult Patients With Partial Onset Seizures

The effectiveness of topiramate as an adjunctive treatment for adults with partial onset seizures was established in six multicenter, randomized, double-blind, placebocontrolled trials, two comparing several dosages of topiramate and placebo and four comparing a single dosage with placebo, in patients with a history of partial onset seizures, with or without secondarily generalized seizures.

Patients in these studies were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX[®] Tablets or placebo. In each study, patients were stabilized on optimum dosages of their concomitant AEDs during baseline phase lasting between 4 and 12 weeks. Patients who experienced a prespecified minimum number of partial onset seizures, with or without secondary generalization, during the baseline phase (12 seizures for 12-week baseline, 8 for 8-week baseline, or 3 for 4-week baseline) were randomly assigned to placebo or a specified dose of TOPAMAX[®] Tablets in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. In five of the six studies, patients received active drug beginning at 100 mg per day; the dose was then increased by 100 mg or 200 mg/day increments weekly or every other week until the assigned dose was reached, unless intolerance prevented increases. In the sixth study (119), the 25 or 50 mg/day initial doses of topiramate were followed by respective weekly increments of 25 or 50 mg/day until the target dose of 200 mg/day was reached. After titration, patients entered a 4, 8, or 12-week stabilization period.

The numbers of patients randomized to each dose, and the actual mean and median doses in the stabilization period are shown in Table 1.

Adjunctive Therapy Controlled Trial in Pediatric Patients Ages 2 - 16 Years With Partial Onset Seizures

The effectiveness of topiramate as an adjunctive treatment for pediatric patients ages 2 - 16 years with partial onset seizures was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing topiramate and placebo in patients with a history of partial onset seizures, with or without secondarily generalized seizures.

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX[®] Tablets or placebo. In this study, patients were stabilized on optimum dosages of their concomitant AEDs during an 8 week baseline phase. Patients who experienced at least six partial onset seizures, with or without secondarily generalized seizures, during the baseline phase were randomly assigned to placebo or TOPAMAX[®] Tablets in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 25 or 50 mg per day; the dose was then increased by 25 mg to 150 mg/day increments every other week until the assigned dosage of 125, 175, 225, or 400 mg/day based on patients' weight to approximate a dosage of 6 mg/kg per day was reached, unless intolerance prevented increases. After titration, patients entered an 8-week stabilization period.

Adjunctive Therapy Controlled Trial in Patients With Primary Generalized Tonic-Clonic Seizures

The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-clonic seizures in patients 2 years old and older was established in a multicenter randomized, double-blind, placebo-controlled trial, comparing a single dosage of topiramate and placebo.

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX[®] or placebo. Patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week baseline phase. Patients who experienced at least three primary generalized tonic-clonic seizures during the baseline phase were randomly assigned to placebo or TOPAMAX[®] in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 50 mg per day for four weeks; the dose was then increased by 50 mg to 150 mg/day increments every other week until the assigned dose of 175, 225, or 400 mg/day based on patients' body weight to approximate a dosage of 6 mg/kg per day was reached, unless intolerance prevented increases. After titration, patients entered a 12-week stabilization period.

Adjunctive Therapy Controlled Trial in Patients With Lennox-Gastaut Syndrome

The effectiveness of topiramate as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome was established in a multicenter, randomized, doubleblind, placebo-controlled trial comparing a single dosage of topiramate with placebo in patients 2 years of age and older.

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX[®] or placebo. Patients who were experiencing at least 60 seizures per month before study entry were stabilized on optimum dosages of their concomitant AEDs during a 4-week baseline phase. Following baseline, patients were randomly assigned to placebo or TOPAMAX[®] in addition to their other AEDs. Active drug was titrated beginning at 1 mg/kg per day for a week; the dose was then increased to 3 mg/kg per day for one week then to 6 mg/kg per day. After titration, patients entered an 8-week stabilization period. The primary measures of effectiveness were the percent reduction in drop attacks and a parental global rating of seizure severity.

		Target Topiramate Dosage (mg/day)					
Protocol		Dlasshað	200	400	(00	200	1 000
Stabili	zation Dose	Placebo ^a	200	400	600	800	1,000
YD	Ν	42	42	40	41		
1D	Mean Dose	5.9	200	390	556		
	Median Dose	6.0	200	400	600		
YE	Ν	44			40	45	40
	Mean Dose	9.7			544	739	796
	Median Dose	10.0			600	800	1,000
Y1	Ν	23		19			
	Mean Dose	3.8		395			
	Median Dose	4.0		400			
Y2	Ν	30			28		
	Mean Dose	5.7			522		
	Median Dose	6.0			600		
Y3	Ν	28				25	
	Mean Dose	7.9				568	
	Median Dose	8.0				600	
119	Ν	90	157				
	Mean Dose	8	200				
	Median Dose	8	200				

Table 1:Topiramate Dose Summary During the Stabilization Periods of Each of Six Double-Blind,
Placebo-Controlled, Add-On Trials in Adults with Partial Onset Seizures^b

^a Placebo dosages are given as the number of tablets. Placebo target dosages were as follows: Protocol Y1, 4 tablets/day; Protocols YD and Y2, 6 tablets/day; Protocol Y3 and 119, 8 tablets/day; Protocol YE, 10 tablets/day.

^b Dose-response studies were not conducted for other indications or pediatric partial onset seizures.

In all add-on trials, the reduction in seizure rate from baseline during the entire double-blind phase was measured. The median percent reductions in seizure rates and the responder rates (fraction of patients with at least a 50% reduction) by treatment group for each study are shown below in Table 2. As described above, a global improvement in seizure severity was also assessed in the Lennox-Gastaut trial.

		_	Target Topiramate Dosage (mg/da					
Protoc	ol Efficacy Results	Placebo	200	400	600	800	1,000	≈6 mg/kg/day³
Partial	Onset Seizures							
Studies	s in Adults							
YD	Ν	45	45	45	46			
	Median % Reduction	11.6	27.2 ^a	47.5 ^b	44.7 ^c			
	% Responders	18	24	44 ^d	46 ^d			
YE	N	47			48	48	47	
	Median % Reduction	1.7			40.8 ^c	41.0 ^c	36.0 ^c	
	% Responders	9			40°	41 ^c	36 ^d	
Y1	N	24		23				
	Median % Reduction	1.1		40.7 ^e				
	% Responders	8		35 ^d				
Y2	Ν	30			30			
	Median % Reduction	-12.2			46.4^{f}			
	% Responders	10			47 ^c			
Y3	Ν	28				28		
	Median % Reduction	-20.6				24.3 ^c		
	% Responders	0				43 ^c		
119	Ν	91	168					
	Median % Reduction	20.0	44.2 ^c					
	% Responders	24	45 ^c					
Studies	s in Pediatric Patients							
YP	Ν	45						41
	Median % Reduction	10.5						33.1 ^d
	% Responders	20						39
	y Generalized							
	Clonic ^h							
YTC	Ν	40						39
	Median % Reduction	9.0						56.7 ^d
	% Responders	20						56 ^c
	x-Gastaut Syndrome ⁱ							
YL	Ν	49						46
	Median % Reduction	-5.1						14.8 ^d
	% Responders	14						28 ^g
	Improvement in Seizure Severity ^j	28						52 ^d

 Table 2:
 Efficacy Results in Double-Blind, Placebo-Controlled, Add-On Trials

Comparisons with placebo: ^a p=0.080; ^b p \leq 0.010; ^c p \leq 0.001; ^d p \leq 0.050; ^e p=0.065; ^f p \leq 0.005; ^g p=0.071; ^h Median % reduction and % responders are reported for PGTC Seizures;

ⁱMedian % reduction and % responders for drop attacks, i.e., tonic or atonic seizures;

^j Percent of subjects who were minimally, much, or very much improved from baseline

* For Protocols YP and YTC, protocol-specified target dosages (<9.3 mg/kg/day) were assigned based on subject's weight to approximate a dosage of 6 mg/kg per day; these dosages corresponded to mg/day dosages of 125, 175, 225, and 400 mg/day.

Subset analyses of the antiepileptic efficacy of TOPAMAX[®] Tablets in these studies showed no differences as a function of gender, race, age, baseline seizure rate, or concomitant AED.

Migraine

The results of 2 multicenter, randomized, double-blind, placebo-controlled, parallelgroup clinical trials established the effectiveness of TOPAMAX[®] in the prophylactic treatment of migraine headache. The design of both trials (one study was conducted in the U.S. and one study was conducted in the U.S. and Canada) was identical, enrolling patients with a history of migraine, with or without aura, for at least 6 months, according to the International Headache Society diagnostic criteria. Patients with a history of cluster headaches or basilar, ophthalmoplegic, hemiplegic, or transformed migraine headaches were excluded from the trials. Patients were required to have completed up to a 2 week washout of any prior migraine preventive medications before starting the baseline phase.

Patients who experienced 3 to 12 migraine headaches over the 4-weeks in the baseline phase were equally randomized to either TOPAMAX[®] 50 mg/day, 100 mg/day, 200 mg/day, or placebo and treated for a total of 26 weeks (8-week titration period and 18-week maintenance period). Treatment was initiated at 25 mg/day for one week, and then the daily dosage was increased by 25-mg increments each week until reaching the assigned target dose or maximum tolerated dose (administered twice daily).

Effectiveness of treatment was assessed by the reduction in migraine headache frequency, as measured by the change in 4-week migraine rate from the baseline phase to double-blind treatment period in each TOPAMAX[®] treatment group compared to placebo in the intent to treat (ITT) population.

In the first study a total of 469 patients (416 females, 53 males), ranging in age from 13 to 70 years, were randomized and provided efficacy data. Two hundred sixty five patients completed the entire 26-week double-blind phase. The median average daily dosages were 47.8 mg/day, 88.3 mg/day, and 132.1 mg/day in the target dose groups of TOPAMAX[®] 50, 100, and 200 mg/day, respectively.

The mean migraine headache frequency rate at baseline was approximately 5.5 migraine headaches/28 days and was similar across treatment groups. The change in the mean 4-week migraine headache frequency from baseline to the double-blind phase was -1.3, -2.1, and -2.2 in the TOPAMAX[®] 50, 100, and 200 mg/day groups, respectively, versus -0.8 in the placebo group (see Figure 2). The differences between the TOPAMAX[®] 100 and 200 mg/day groups versus placebo were statistically significant (p<0.001 for both comparisons).

In the second study a total of 468 patients (406 females, 62 males), ranging in age from 12 to 65 years, were randomized and provided efficacy data. Two hundred fifty five patients completed the entire 26-week double-blind phase. The median average daily dosages were 46.5 mg/day, 85.6 mg/day, and 150.2 mg/day in the target dose groups of TOPAMAX[®] 50, 100, and 200 mg/day, respectively.

The mean migraine headache frequency rate at baseline was approximately 5.5 migraine headaches/28 days and was similar across treatment groups. The change in the mean 4-week migraine headache period frequency from baseline to the double-blind phase was -1.4, -2.1, and -2.4 in the TOPAMAX[®] 50, 100, and 200 mg/day groups, respectively, versus -1.1 in the placebo group (see Figure 2). The differences between the TOPAMAX[®] 100 and 200 mg/day groups versus placebo were statistically significant (p=0.008 and <0.001, respectively).

In both studies, there were no apparent differences in treatment effect within age, or gender, subgroups. Because most patients were Caucasian, there were insufficient numbers of patients from different races to make a meaningful comparison of race.




Figure 2: Reduction in 4-Week Migraine Headache Frequency (Studies TOPMAT-MIGR-001 and TOPMAT-MIGR-002)

* p <0.010, ** p <0.001

INDICATIONS AND USAGE

Monotherapy Epilepsy

TOPAMAX® (topiramate) Tablets and TOPAMAX® (topiramate capsules) Sprinkle Capsules are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures.

Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

Adjunctive Therapy Epilepsy

TOPAMAX[®] (topiramate) Tablets and TOPAMAX[®] (topiramate capsules) Sprinkle Capsules are indicated as adjunctive therapy for adults and pediatric patients ages 2 - 16 years with partial onset seizures, or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome.

Migraine

TOPAMAX[®] (topiramate) Tablets and TOPAMAX[®] (topiramate capsules) Sprinkle Capsules are indicated for adults for the prophylaxis of migraine headache. The usefulness of TOPAMAX[®] in the acute treatment of migraine headache has not been studied.

CONTRAINDICATIONS

TOPAMAX[®] is contraindicated in patients with a history of hypersensitivity to any component of this product.

WARNINGS

Metabolic Acidosis

Hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis) is associated with topiramate treatment. This metabolic acidosis is caused by renal bicarbonate loss due to the inhibitory effect of topiramate on carbonic anhydrase. Such electrolyte imbalance has been observed with the use of topiramate in placebo-controlled clinical trials and in the post-marketing period. Generally, topiramate-induced metabolic acidosis occurs early in treatment although cases can

occur at any time during treatment. Bicarbonate decrements are usually mildmoderate (average decrease of 4 mEq/L at daily doses of 400 mg in adults and at approximately 6 mg/kg/day in pediatric patients); rarely, patients can experience severe decrements to values below 10 mEq/L. Conditions or therapies that predispose to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, surgery, ketogenic diet, or drugs) may be additive to the bicarbonate lowering effects of topiramate.

In adults, the incidence of persistent treatment-emergent decreases in serum bicarbonate (levels of <20 mEq/L at two consecutive visits or at the final visit) in controlled clinical trials for adjunctive treatment of epilepsy was 32% for 400 mg/day, and 1% for placebo. Metabolic acidosis has been observed at doses as low as 50 mg/day. The incidence of persistent treatment-emergent decreases in serum bicarbonate in adults in the epilepsy controlled clinical trial for monotherapy was 15% for 50 mg/day and 25% for 400 mg/day. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in the adjunctive therapy trials was 3% for 400 mg/day, and 0% for placebo and in the monotherapy trial was 1% for 50 mg/day and 7% for 400 mg/day. Serum bicarbonate levels have not been systematically evaluated at daily doses greater than 400 mg/day.

In pediatric patients (<16 years of age), the incidence of persistent treatmentemergent decreases in serum bicarbonate in placebo-controlled trials for adjunctive treatment of Lennox-Gastaut syndrome or refractory partial onset seizures was 67% for TOPAMAX (at approximately 6 mg/kg/day), and 10% for placebo. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in these trials was 11% for TOPAMAX and 0% for placebo. Cases of moderately severe metabolic acidosis have been reported in patients as young as 5 months old, especially at daily doses above 5 mg/kg/day.

In pediatric patients (10 years up to 16 years of age), the incidence of persistent treatment-emergent decreases in serum bicarbonate in the epilepsy controlled clinical trial for monotherapy was 7% for 50 mg/day and 20% for 400 mg/day. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in this trial was 4% for 50 mg/day and 4% for 400 mg/day.

The incidence of persistent treatment-emergent decreases in serum bicarbonate in placebo-controlled trials for adults for prophylaxis of migraine was 44% for 200 mg/day, 39% for 100 mg/day, 23% for 50 mg/day, and 7% for placebo. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in these trials was 11% for 200 mg/day, 9% for 100 mg/day, 2% for 50 mg/day, and <1% for placebo.

Some manifestations of acute or chronic metabolic acidosis may include hyperventilation, nonspecific symptoms such as fatigue and anorexia, or more severe sequelae including cardiac arrhythmias or stupor. Chronic, untreated metabolic acidosis may increase the risk for nephrolithiasis or nephrocalcinosis, and may also result in osteomalacia (referred to as rickets in pediatric patients) and/or osteoporosis with an increased risk for fractures. Chronic metabolic acidosis in pediatric patients may also reduce growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of topiramate on growth and bone-related sequelae has not been systematically investigated.

Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face of persistent acidosis, alkali treatment should be considered.

Acute Myopia and Secondary Angle Closure Glaucoma

A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving TOPAMAX[®]. Symptoms include acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemia (redness) and increased intraocular pressure. Mydriasis may or may not be present. This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating TOPAMAX[®] therapy. In contrast to primary narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with topiramate has been reported in pediatric patients as well as adults. The primary treatment to reverse symptoms is discontinuation of TOPAMAX[®] as rapidly as possible, according to the judgment of the treating

physician. Other measures, in conjunction with discontinuation of TOPAMAX[®], may be helpful.

Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss.

Oligohidrosis and Hyperthermia

Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with TOPAMAX[®] use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures.

The majority of the reports have been in children. Patients, especially pediatric patients, treated with TOPAMAX[®] should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather. Caution should be used when TOPAMAX[®] is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.

Withdrawal of AEDs

Antiepileptic drugs, including TOPAMAX[®], should be withdrawn gradually to minimize the potential of increased seizure frequency.

Cognitive/Neuropsychiatric Adverse Events

<u>Adults</u>

Adverse events most often associated with the use of TOPAMAX[®] were related to the central nervous system and were observed in both the epilepsy and migraine populations. In adults, the most frequent of these can be classified into three general categories: 1) Cognitive-related dysfunction (e.g. confusion, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language problems, particularly word-finding difficulties); 2) Psychiatric/behavioral disturbances (e.g. depression or mood problems); and 3) Somnolence or fatigue.

Cognitive-Related Dysfunction

The majority of cognitive-related adverse events were mild to moderate in severity, and they frequently occurred in isolation. Rapid titration rate and higher initial dose were associated with higher incidences of these events. Many of these events contributed to withdrawal from treatment [see ADVERSE REACTIONS, Table 4, Table 6, and Table 10].

In the original add-on epilepsy controlled trials (using rapid titration such as 100-200 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse events was 42% for 200 mg/day, 41% for 400 mg/day, 52% for 600 mg/day, 56% for 800 and 1000 mg/day, and 14% for placebo. These dose-related adverse reactions began with a similar frequency in the titration or in the maintenance phase, although in some patients the events began during titration and persisted into the maintenance phase. Some patients who experienced one or more cognitive-related adverse events in the titration phase had a dose-related recurrence of these events in the maintenance phase.

In the monotherapy epilepsy controlled trial, the proportion of patients who experienced one or more cognitive-related adverse events was 19% for TOPAMAX[®] 50 mg/day and 26% for 400 mg/day.

In the 6-month migraine prophylaxis controlled trials using a slower titration regimen (25 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse events was 19% for TOPAMAX[®] 50 mg/day, 22% for 100 mg/day, 28% for 200 mg/day, and 10% for placebo. These dose-related adverse reactions typically began in the titration phase and often persisted into the maintenance phase, but infrequently began in the maintenance phase. Some patients experienced a recurrence of one or more of these cognitive adverse events and this recurrence was typically in the titration phase. A relatively small proportion of topiramate-treated patients experienced more than one concurrent cognitive adverse event. The most common cognitive adverse events occurring together included difficulty with memory along with difficulty with concentration/attention, difficulty with memory along with language problems, and difficulty with concentration/attention along with language problems. Rarely, topiramate-treated patients experienced three concurrent cognitive events.

Psychiatric/Behavioral Disturbances

Psychiatric/behavioral disturbances (depression or mood problems) were dose-related for both the epilepsy and migraine populations.

Somnolence/Fatigue

Somnolence and fatigue were the adverse events most frequently reported during clinical trials of TOPAMAX[®] for adjunctive epilepsy. For the adjunctive epilepsy population, the incidence of somnolence did not differ substantially between 200 mg/day and 1000 mg/day, but the incidence of fatigue was dose-related and increased

at dosages above 400 mg/day. For the monotherapy epilepsy population in the 50 mg/day and 400 mg/day groups, the incidence of somnolence was dose-related (9% for the 50 mg/day group and 15% for the 400 mg/day group) and the incidence of fatigue was comparable in both treatment groups (14% each). For the migraine population, fatigue and somnolence were dose-related and more common in the titration phase.

Additional nonspecific CNS events commonly observed with topiramate in the addon epilepsy population include dizziness or ataxia.

Pediatric Patients

In double-blind adjunctive therapy and monotherapy epilepsy clinical studies, the incidences of cognitive/neuropsychiatric adverse events in pediatric patients were generally lower than observed in adults. These events included psychomotor slowing, difficulty with concentration/attention, speech disorders/related speech problems and language problems. The most frequently reported neuropsychiatric events in pediatric patients during adjunctive therapy double-blind studies were somnolence and fatigue. The most frequently reported neuropsychiatric events in the 50 mg/day and 400 mg/day groups during the monotherapy double-blind study were headache, dizziness anorexia, and somnolence.

No patients discontinued treatment due to any adverse events in the adjunctive epilepsy double-blind trials. In the monotherapy epilepsy double-blind trial, 1 pediatric patient (2%) in the 50 mg/day group and 7 pediatric patients (12%) in the 400 mg/day group discontinued treatment due to any adverse events. The most common adverse event associated with discontinuation of therapy was difficulty with concentration/attention; all occurred in the 400 mg/day group.

Sudden Unexplained Death in Epilepsy (SUDEP)

During the course of premarketing development of TOPAMAX[®] (topiramate) Tablets, 10 sudden and unexplained deaths were recorded among a cohort of treated patients (2,796 subject years of exposure). This represents an incidence of 0.0035 deaths per patient year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving TOPAMAX[®] (ranging from 0.0005 for the general population of patients with epilepsy, to 0.003 for a clinical trial population similar to that in the TOPAMAX[®] program, to 0.005 for patients with refractory epilepsy).

PRECAUTIONS

Hyperammonemia and Encephalopathy Associated with Concomitant Valproic Acid Use

Concomitant administration of topiramate and valproic acid has been associated with hyperammonemia with or without encephalopathy in patients who have tolerated either drug alone. Clinical symptoms of hyperammonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting. In most cases, symptoms and signs abated with discontinuation of either drug. This adverse event is not due to a pharmacokinetic interaction.

It is not known if topiramate monotherapy is associated with hyperammonemia.

Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity may be at an increased risk for hyperammonemia with or without encephalopathy. Although not studied, an interaction of topiramate and valproic acid may exacerbate existing defects or unmask deficiencies in susceptible persons.

In patients who develop unexplained lethargy, vomiting, or changes in mental status, hyperammonemic encephalopathy should be considered and an ammonia level should be measured.

Kidney Stones

A total of 32/2,086 (1.5%) of adults exposed to topiramate during its adjunctive epilepsy therapy development reported the occurrence of kidney stones, an incidence about 2-4 times greater than expected in a similar, untreated population. In the double-blind monotherapy epilepsy study, a total of 4/319 (1.3%) of adults exposed to topiramate reported the occurrence of kidney stones. As in the general population, the incidence of stone formation among topiramate treated patients was higher in men. Kidney stones have also been reported in pediatric patients.

An explanation for the association of TOPAMAX[®] and kidney stones may lie in the fact that topiramate is a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, promote stone formation by reducing urinary citrate excretion and by increasing urinary pH. The concomitant use of TOPAMAX[®] with other carbonic anhydrase inhibitors or potentially in patients on a ketogenic diet may create a physiological environment that increases the risk of kidney stone formation, and should therefore be avoided.

Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recommended to reduce new stone formation.

Paresthesia

Paresthesia (usually tingling of the extremities), an effect associated with the use of other carbonic anhydrase inhibitors, appears to be a common effect of TOPAMAX[®]. Paresthesia was more frequently reported in the monotherapy epilepsy trials and migraine prophylaxis trials versus the adjunctive therapy epilepsy trials. In the majority of instances, paresthesia did not lead to treatment discontinuation.

Adjustment of Dose in Renal Failure

The major route of elimination of unchanged topiramate and its metabolites is via the kidney. Dosage adjustment may be required in patients with reduced renal function (see **DOSAGE AND ADMINISTRATION**).

Decreased Hepatic Function

In hepatically impaired patients, topiramate should be administered with caution as the clearance of topiramate may be decreased.

Information for Patients

Patients taking TOPAMAX[®] should be told to seek immediate medical attention if they experience blurred vision or periorbital pain.

Patients, especially pediatric patients, treated with TOPAMAX[®] should be monitored closely for evidence of decreased sweating and increased body temperature, especially in hot weather.

Patients, particularly those with predisposing factors, should be instructed to maintain an adequate fluid intake in order to minimize the risk of renal stone formation [see **PRECAUTIONS: Kidney Stones**, for support regarding hydration as a preventative measure].

Patients should be warned about the potential for somnolence, dizziness, confusion, and difficulty concentrating and advised not to drive or operate machinery until they have gained sufficient experience on topiramate to gauge whether it adversely affects their mental and/or motor performance.

Additional food intake may be considered if the patient is losing weight while on this medication.

Please refer to the end of the product labeling for important information on how to take TOPAMAX[®] (topiramate capsules) Sprinkle Capsules.

Laboratory Tests:

Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended (see **WARNINGS**).

Drug Interactions:

In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 isozymes.

Antiepileptic Drugs

Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effects of these interactions on mean plasma AUCs are summarized in Table 3.

In Table 3, the second column (AED concentration) describes what happens to the concentration of the AED listed in the first column when topiramate is added.

The third column (topiramate concentration) describes how the coadministration of a drug listed in the first column modifies the concentration of topiramate in experimental settings when TOPAMAX[®] was given alone.

Table 3: Summary of AED Interactions with TOPAMAX [®]							
AED	AED	Topiramate					
Co-administered	Concentration	Concentration					
Phenytoin	NC or 25% increase ^a	48% decrease					
Carbamazepine (CBZ)	NC	40% decrease					
CBZ epoxide ^b	NC	NE					
Valproic acid	11% decrease	14% decrease					
Phenobarbital	NC	NE					
Primidone	NC	NE					
Lamotrigine	NC at TPM doses up	15% increase					
	to 400 mg/day						

^a = Plasma concentration increased 25% in some patients, generally those on a b.i.d. dosing regimen of phenytoin.

^b = Is not administered but is an active metabolite of carbamazepine.

NC = Less than 10% change in plasma concentration.

AED = Antiepileptic drug.

NE = Not Evaluated.

TPM - Topiramate

In addition to the pharmacokinetic interaction described in the above table, concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy (see **PRECAUTIONS**, Hyperammonemia and Encephalopathy Associated with Concomitant Valproic Acid Use).

Other Drug Interactions

Digoxin: In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant TOPAMAX[®] administration. The clinical relevance of this observation has not been established.

CNS Depressants: Concomitant administration of TOPAMAX[®] and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse events, topiramate should be used with extreme caution if used in combination with alcohol and other CNS depressants.

Oral Contraceptives: In a pharmacokinetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), TOPAMAX[®] given in the absence of other medications at doses of 50 to 200 mg/day was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. In another study, exposure to EE was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when given as adjunctive therapy in patients taking valproic acid. In both studies, TOPAMAX[®] (50 mg/day to 800 mg/day) did not significantly affect exposure to NET. Although there was a dose dependent decrease in EE exposure for doses between 200-800 mg/day, there was no significant dose dependent change in EE exposure for doses of 50-200 mg/day. The clinical significance of the changes observed is not known. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with TOPAMAX[®]. Patients taking estrogen containing contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.

Hydrochlorothiazide (HCTZ): A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of HCTZ (25 mg q24h) and topiramate (96 mg q12h) when administered alone and concomitantly. The results of this study indicate that topiramate C_{max} increased by 27% and AUC increased by 29% when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate dose. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination.

Pioglitazone: A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate and pioglitazone when administered alone and concomitantly. A 15% decrease in the AUC_{τ ,ss} of pioglitazone with no alteration in C_{max,ss} was observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in C_{max,ss} and AUC_{τ ,ss} respectively, of the active hydroxy-metabolite was noted as well as a 60% decrease in C_{max,ss} and AUC_{τ ,ss} of the active keto-metabolite. The clinical significance of these findings is not known. When TOPAMAX[®] is added to pioglitazone therapy or pioglitazone is added to TOPAMAX[®] therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.

Lithium: Multiple dosing of topiramate 100 mg every 12 hrs decreased the AUC and C_{max} of Lithium (300 mg every 8 hrs) by 20% (N=12, 6 M; 6 F).

Haloperidol: The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of topiramate (100 mg every 12 hr) in 13 healthy adults (6 M, 7 F).

Amitriptyline: There was a 12% increase in AUC and C_{max} for amitriptyline (25 mg per day) in 18 normal subjects (9 male; 9 female) receiving 200 mg/day of topiramate. Some subjects may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose

should be made according to the patient's clinical response and not on the basis of plasma levels.

Sumatriptan: Multiple dosing of topiramate (100 mg every 12 hrs) in 24 healthy volunteers (14 M, 10 F) did not affect the pharmacokinetics of single dose sumatriptan either orally (100 mg) or subcutaneously (6 mg).

Risperidone: There was a 25% decrease in exposure to risperidone (2 mg single dose) in 12 healthy volunteers (6 M, 6 F) receiving 200 mg/day of topiramate. Therefore, patients receiving risperidone in combination with topiramate should be closely monitored for clinical response.

Propranolol: Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 M, 17 F) did not affect the pharmacokinetics of propranolol following daily 160 mg doses. Propranolol doses of 160 mg/day in 39 volunteers (27M, 12F) had no effect on the exposure to topiramate at a dose of 200 mg/day of topiramate.

Dihydroergotamine: Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 M, 12 F) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamine. Similarly, a 1 mg subcutaneous dose of dihydroergotamine did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study.

Others: Concomitant use of TOPAMAX[®], a carbonic anhydrase inhibitor, with other carbonic anhydrase inhibitors, e.g., acetazolamide or dichlorphenamide, may create a physiological environment that increases the risk of renal stone formation, and should therefore be avoided.

Drug/Laboratory Test Interactions There are no known interactions of topiramate with commonly used laboratory tests.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

An increase in urinary bladder tumors was observed in mice given topiramate (20, 75, and 300 mg/kg) in the diet for 21 months. The elevated bladder tumor incidence, which was statistically significant in males and females receiving 300 mg/kg, was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. Plasma exposures in mice receiving 300 mg/kg were approximately 0.5 to 1 times steady-state exposures measured in patients receiving topiramate monotherapy at the recommended human dose (RHD) of 400

mg, and 1.5 to 2 times steady- state topiramate exposures in patients receiving 400 mg of topiramate plus phenytoin. The relevance of this finding to human carcinogenic risk is uncertain. No evidence of carcinogenicity was seen in rats following oral administration of topiramate for 2 years at doses up to 120 mg/kg (approximately 3 times the RHD on a mg/m² basis).

Topiramate did not demonstrate genotoxic potential when tested in a battery of *in vitro* and *in vivo* assays. Topiramate was not mutagenic in the Ames test or the *in vitro* mouse lymphoma assay; it did not increase unscheduled DNA synthesis in rat hepatocytes *in vitro*; and it did not increase chromosomal aberrations in human lymphocytes *in vitro* or in rat bone marrow *in vivo*.

No adverse effects on male or female fertility were observed in rats at doses up to 100 mg/kg (2.5 times the RHD on a mg/m² basis).

Pregnancy: Pregnancy Category C.

Topiramate has demonstrated selective developmental toxicity, including teratogenicity, in experimental animal studies. When oral doses of 20, 100, or 500 mg/kg were administered to pregnant mice during the period of organogenesis, the incidence of fetal malformations (primarily craniofacial defects) was increased at all doses. The low dose is approximately 0.2 times the recommended human dose (RHD=400 mg/day) on a mg/m² basis. Fetal body weights and skeletal ossification were reduced at 500 mg/kg in conjunction with decreased maternal body weight gain.

In rat studies (oral doses of 20, 100, and 500 mg/kg or 0.2, 2.5, 30 and 400 mg/kg), the frequency of limb malformations (ectrodactyly, micromelia, and amelia) was increased among the offspring of dams treated with 400 mg/kg (10 times the RHD on a mg/m^2 basis) or greater during the organogenesis period of pregnancy. Embryotoxicity (reduced fetal body weights, increased incidence of structural variations) was observed at doses as low as 20 mg/kg (0.5 times the RHD on a mg/m² basis). Clinical signs of maternal toxicity were seen at 400 mg/kg and above, and maternal body weight gain was reduced during treatment with 100 mg/kg or greater.

In rabbit studies (20, 60, and 180 mg/kg or 10, 35, and 120 mg/kg orally during organogenesis), embryo/fetal mortality was increased at 35 mg/kg (2 times the RHD on a mg/m² basis) or greater, and teratogenic effects (primarily rib and vertebral malformations) were observed at 120 mg/kg (6 times the RHD on a mg/m² basis).

Evidence of maternal toxicity (decreased body weight gain, clinical signs, and/or mortality) was seen at 35 mg/kg and above.

When female rats were treated during the latter part of gestation and throughout lactation (0.2, 4, 20, and 100 mg/kg or 2, 20, and 200 mg/kg), offspring exhibited decreased viability and delayed physical development at 200 mg/kg (5 times the RHD on a mg/m² basis) and reductions in pre- and/or postweaning body weight gain at 2 mg/kg (0.05 times the RHD on a mg/m² basis) and above. Maternal toxicity (decreased body weight gain, clinical signs) was evident at 100 mg/kg or greater.

In a rat embryo/fetal development study with a postnatal component (0.2, 2.5, 30 or 400 mg/kg during organogenesis; noted above), pups exhibited delayed physical development at 400 mg/kg (10 times the RHD on a mg/m² basis) and persistent reductions in body weight gain at 30 mg/kg (1 times the RHD on a mg/m² basis) and higher.

There are no studies using TOPAMAX[®] in pregnant women. TOPAMAX[®] should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.

In post-marketing experience, cases of hypospadias have been reported in male infants exposed in utero to topiramate, with or without other anticonvulsants; however, a causal relationship with topiramate has not been established.

Labor and Delivery:

In studies of rats where dams were allowed to deliver pups naturally, no drug-related effects on gestation length or parturition were observed at dosage levels up to 200 mg/kg/day.

The effect of TOPAMAX[®] on labor and delivery in humans is unknown.

Nursing Mothers:

Topiramate is excreted in the milk of lactating rats. The excretion of topiramate in human milk has not been evaluated in controlled studies. Limited observations in patients suggest an extensive secretion of topiramate into breast milk. Since many drugs are excreted in human milk, and because the potential for serious adverse reactions in nursing infants to TOPAMAX[®] is unknown, the potential benefit to the mother should be weighed against the potential risk to the infant when considering recommendations regarding nursing.

Pediatric Use:

Safety and effectiveness in patients below the age of 2 years have not been established for the adjunctive therapy treatment of partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. Safety and effectiveness in patients below the age of 10 years have not been established for the monotherapy treatment of epilepsy. Topiramate is associated with metabolic acidosis. Chronic untreated metabolic acidosis in pediatric patients may cause osteomalacia/rickets and may reduce growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of topiramate on growth and bone-related sequelae has not been systematically investigated (see **WARNINGS**).

Safety and effectiveness in pediatric patients have not been established for the prophylaxis treatment of migraine headache.

Geriatric Use:

In clinical trials, 3% of patients were over 60. No age related difference in effectiveness or adverse effects were evident. However, clinical studies of topiramate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Dosage adjustment may be necessary for elderly with impaired renal function (creatinine clearance rate \leq 70 mL/min/1.73 m²) due to reduced clearance of topiramate (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

Race and Gender Effects:

Evaluation of effectiveness and safety in clinical trials has shown no race or gender related effects.

ADVERSE REACTIONS

The data described in the following section were obtained using TOPAMAX[®] (topiramate) Tablets.

Monotherapy Epilepsy

The adverse events in the controlled trial that occurred most commonly in adults in the 400 mg/day group and at a rate higher than the 50 mg/day group were: paresthesia, weight decrease, somnolence, anorexia, dizziness, and difficulty with memory NOS [see Table 4].

The adverse events in the controlled trial that occurred most commonly in children (10 years up to 16 years of age) in the 400 mg/day group and at a rate higher than the 50 mg/day group were: weight decrease, upper respiratory tract infection, paresthesia, anorexia, diarrhea, and mood problems [see Table 5].

Approximately 21% of the 159 adult patients in the 400 mg/day group who received topiramate as monotherapy in the controlled clinical trial discontinued therapy due to adverse events. Adverse events associated with discontinuing therapy (\geq 2%) included depression, insomnia, difficulty with memory (NOS), somnolence, paresthesia, psychomotor slowing, dizziness, and nausea.

Approximately 12% of the 57 pediatric patients in the 400 mg/day group who received topiramate as monotherapy in the controlled clinical trial discontinued therapy due to adverse events. Adverse events associated with discontinuing therapy (\geq 5%) included difficulty with concentration/attention.

The prescriber should be aware that these data cannot be used to predict the frequency of adverse events in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during the clinical study. Similarly, the cited frequencies cannot be directly compared with data obtained from other clinical investigations involving different treatments, uses, or investigators. Inspection of these frequencies, however, does provide the prescribing physician with a basis to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied.

	TOPAMAX [®] Dosage (mg/day)			
Body System/	50	400		
Adverse Event	(N= 160)	(N=159)		
Body as a Whole-General Disorders				
Asthenia	4	6		
Leg Pain	2	3		
Chest Pain	1	2		
Central & Peripheral Nervous System Disorders				
Paresthesia	21	40		
Dizziness	13	14		
Hypoaesthesia	4	5		
Ataxia	3	4		
Hypertonia	Õ	3		
Gastro-Intestinal System Disorders	Ű	5		
Diarrhea	5	6		
Constipation	1	4		
Gastritis	0	3		
Dry Mouth	1	3 2		
Gastroesophageal Reflux	1	2		
Liver and Biliary System Disorders		2		
Gamma-GT Increased	1	3		
Metabolic and Nutritional Disorders				
Weight Decrease	6	16		
Psychiatric Disorders				
Somnolence	9	15		
Anorexia	4	14		
Difficulty with Memory NOS	5	10		
Insomnia	8	9		
Depression	7	9		
Difficulty with Concentration/Attention	7	8		
Anxiety	4	6		
Psychomotor Slowing	3	5		
Mood Problems	2	5		
Confusion	3	4		
Cognitive Problem NOS	1	4		
Libido Decreased	0	3		
	0	5		
Reproductive Disorders, Female	0	3		
Vaginal Hemorrhage	0	3		
Red Blood Cell Disorders		2		
Anemia	1	2		
Resistance Mechanism Disorders				
Infection Viral	6	8		
Infection	2	3		
Respiratory System Disorders				
Bronchitis	3	4		
Rhinitis	2	4		
Dyspnea	1	2		
Skin and Appendages Disorders				
Rash	1	4		
Pruritus	1	4		
Acne	2	3		
Special Senses Other, Disorders	-	-		
Taste Perversion	3	5		
Urinary System Disorders	5	2		
Cystitis	1	3		
Renal Calculus	1	3		
	0			
Urinary Tract Infection	1	2		
Dysuria	0	2		
Micturition Frequency ^a Values represent the percentage of patients reporting a given adverse	0	2		

 Table 4:
 Incidence of Treatment-Emergent Adverse Events in the Monotherapy Epilepsy Trial in Adults^a Where Rate Was at Least 2% in the 400 mg/day Topiramate Group and Greater Than the Rate in the 50 mg/day Topiramate Group

Values represent the percentage of patients reporting a given adverse event. Patients may have reported more than one adverse event during the study and can be included in more than one adverse event category.

Than the Rate in the 50 mg/day Topiramate Group			
	TOPAMAX [®] I	Dosage (mg/day) ^b	
Body System/	50	400	
Adverse Event	(N=57)	(N=57)	
Body as a Whole-General Disorders			
Fever	0	9	
Central & Peripheral Nervous System Disorders			
Paresthesia	2	16	
Gastro-Intestinal System Disorders			
Diarrhea	5	11	
Metabolic and Nutritional Disorders			
Weight Decrease	7	21	
Psychiatric Disorders			
Anorexia	11	14	
Mood Problems	2	11	
Difficulty with Concentration/Attention	4	9	
Cognitive Problems NOS	0	7	
Nervousness	4	5	
Resistance Mechanism Disorders			
Infection Viral	4	9	
Infection	2	7	
Respiratory System Disorders			
Upper Respiratory Tract Infection	16	18	
Rhinitis	2	7	
Bronchitis	2	7	
Sinusitis	2	5	
Skin and Appendages Disorders			
Alopecia	2	5	

Table 5:	Incidence of Treatment-Emergent Adverse Events in the Monotherapy Epilepsy Trial in Children Ages
	10 up to 16 Years ^a Where Rate Was at Least 5% in the 400 mg/day Topiramate Group and Greater
	Than the Rate in the 50 mg/day Topiramate Group

Values represent the percentage of patients reporting a given adverse event. Patients may have reported more than one adverse event during the study and can be included in more than one adverse event category.

Adjunctive Therapy Epilepsy

The most commonly observed adverse events associated with the use of topiramate at dosages of 200 to 400 mg/day in controlled trials in adults with partial onset seizures, primary generalized tonic-clonic seizures, or Lennox-Gastaut syndrome, that were seen at greater frequency in topiramate-treated patients and did not appear to be dose-related were: somnolence, dizziness, ataxia, speech disorders and related speech problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia and diplopia [see Table 6]. The most common dose-related adverse events at dosages of 200 to 1,000 mg/day were: fatigue, nervousness, difficulty with concentration or attention, confusion, depression, anorexia, language problems, anxiety, mood problems, and weight decrease [see Table 8].

Adverse events associated with the use of topiramate at dosages of 5 to 9 mg/kg/day in controlled trials in pediatric patients with partial onset seizures, primary generalized tonic-clonic seizures, or Lennox-Gastaut syndrome, that were seen at greater frequency in topiramate-treated patients were: fatigue, somnolence, anorexia, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease [see Table 9].

In controlled clinical trials in adults, 11% of patients receiving topiramate 200 to 400 mg/day as adjunctive therapy discontinued due to adverse events. This rate appeared to increase at dosages above 400 mg/day. Adverse events associated with discontinuing therapy included somnolence, dizziness, anxiety, difficulty with concentration or attention, fatigue, and paresthesia and increased at dosages above 400 mg/day. None of the pediatric patients who received topiramate adjunctive therapy at 5 to 9 mg/kg/day in controlled clinical trials discontinued due to adverse events.

Approximately 28% of the 1,757 adults with epilepsy who received topiramate at dosages of 200 to 1,600 mg/day in clinical studies discontinued treatment because of adverse events; an individual patient could have reported more than one adverse event. These adverse events were: psychomotor slowing (4.0%), difficulty with memory (3.2%), fatigue (3.2%), confusion (3.1%), somnolence (3.2%), difficulty with concentration/attention (2.9%), anorexia (2.7%), depression (2.6%), dizziness (2.5%), weight decrease (2.5%), nervousness (2.3%), ataxia (2.1%), and paresthesia (2.0%). Approximately 11% of the 310 pediatric patients who received topiramate at dosages up to 30 mg/kg/day discontinued due to adverse events. Adverse events associated with discontinuing therapy included aggravated convulsions (2.3%), difficulty with concentration/attention (1.6%), language problems (1.3%), personality disorder (1.3%), and somnolence (1.3%).

Incidence in Epilepsy Controlled Clinical Trials Adjunctive Therapy– Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, and Lennox-Gastaut Syndrome

Table 6 lists treatment-emergent adverse events that occurred in at least 1% of adults treated with 200 to 400 mg/day topiramate in controlled trials that were numerically more common at this dose than in the patients treated with placebo. In general, most patients who experienced adverse events during the first eight weeks of these trials no longer experienced them by their last visit. Table 9 lists treatment-emergent adverse events that occurred in at least 1% of pediatric patients treated with 5 to 9 mg/kg topiramate in controlled trials that were numerically more common than in patients treated with placebo.

The prescriber should be aware that these data were obtained when TOPAMAX[®] was added to concurrent antiepileptic drug therapy and cannot be used to predict the frequency of adverse events in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with data obtained from other clinical investigations involving different treatments, uses, or investigators. Inspection of these frequencies, however, does provide the prescribing physician with a basis to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied.

Other Adverse Events Observed During Double-Blind Adjunctive Therapy Epilepsy Trials

Other events that occurred in more than 1% of adults treated with 200 to 400 mg of topiramate in placebo-controlled epilepsy trials but with equal or greater frequency in the placebo group were: headache, injury, anxiety, rash, pain, convulsions aggravated, coughing, fever, diarrhea, vomiting, muscle weakness, insomnia, personality disorder, dysmenorrhea, upper respiratory tract infection, and eye pain.

Treated Patients	TOPAMAX [®] Dosage (mg/day)			
Body System/	Placebo	200-400	600-1,000	
Adverse Event ^c	(N=291)	(N=183)	(N=414)	
Body as a Whole-General Disorders			· · · · ·	
Fatigue	13	15	30	
Asthenia	1	6	3	
Back Pain	4	5	3	
Chest Pain	3	4	2	
Influenza-Like Symptoms	2	3	4	
Leg Pain	2	2	4	
Hot Flushes	1	2	1	
Allergy	1	2	3	
Edema	1	2	1	
Body Odor	0	1	0	
Rigors	0	1	<1	
Central & Peripheral Nervous System Disorders	÷	-	-	
Dizziness	15	25	32	
Ataxia	7	16	14	
Speech Disorders/Related Speech Problems	2	13	11	
Paresthesia	4	11	19	
Nystagmus	7	10	11	
Tremor	6	9	9	
Language Problems	1	6	10	
Coordination Abnormal	2	4	4	
Hypoaesthesia	1	2	1	
Gait Abnormal	1	$\frac{2}{3}$	2	
Muscle Contractions Involuntary	1	2	2	
	0	$\frac{2}{2}$	1	
Stupor Vertigo	0	1	2	
Gastro-Intestinal System Disorders	1	I	2	
Nausea	8	10	12	
	8 6	10 7	6	
Dyspepsia				
Abdominal Pain	4 2	6	7	
Constipation		4	3	
Gastroenteritis	1	2	1	
Dry Mouth	1	2	4	
Gingivitis	<1	1	1	
GI Disorder	<1	1	0	
Hearing and Vestibular Disorders	1	2	1	
Hearing Decreased	1	2	1	
Metabolic and Nutritional Disorders		2	10	
Weight Decrease	3	9	13	
Muscle-Skeletal System Disorders			•	
Myalgia	1	2	2	
Skeletal Pain	0	1	0	
Platelet, Bleeding, & Clotting Disorders				
Epistaxis	1	2	1	
Psychiatric Disorders	10	•	•	
Somnolence	12	29	28	
Nervousness	6	16	19	
Psychomotor Slowing	2	13	21	
Difficulty with Memory	3	12	14	
Anorexia	4	10	12	
Confusion	5	11	14	
Depression	5	5	13	
Difficulty with Concentration/Attention	2	6	14	
Mood Problems	2	4	9	
Agitation	2	3	3	
Aggressive Reaction	2	3	3	
Emotional Lability	1	3	3	
Cognitive Problems	1	3	3	
Libido Decreased	1	2	<1	

 Table 6:
 Incidence of Treatment-Emergent Adverse Events in Placebo-Controlled, Add-On Epilepsy Trials in Adults^{a,b} Where Rate Was > 1% in Any Topiramate Group and Greater Than the Rate in Placebo-Treated Patients

Apathy	1	1	3
Depersonalization	1	1	2
			(Continued)

Table 6:	Incidence of	Treatment-Emergent Adverse Events in Placebo-Controlled, Add-On Epilepsy Trials in
	Adults ^{a,b}	Where Rate Was > 1% in Any Topiramate Group and Greater Than the Rate in Placebo-
	Treated Patie	ents (Continued)

, , , , , , , , , , , , , , , , , , ,	TOPAMAX [®] Dosage (mg/day)				
Body System/	Placebo	200-400	600-1,000		
Adverse Event ^c	(N=291)	(N=183)	(N=414)		
Reproductive Disorders, Female	\$ <i>``</i>	, ,	· · · ·		
Breast Pain	2	4	0		
Amenorrhea	1	2	2		
Menorrhagia	0	2	1		
Menstrual Disorder	1	2	1		
Reproductive Disorders, Male					
Prostatic Disorder	<1	2	0		
Resistance Mechanism Disorders					
Infection	1	2	1		
Infection Viral	1	2	<1		
Moniliasis	<1	1	0		
Respiratory System Disorders					
Pharyngitis	2	6	3		
Rhinitis	6	7	6		
Sinusitis	4	5	6		
Dyspnea	1	1	2		
Skin and Appendages Disorders					
Skin Disorder	<1	2	1		
Sweating Increased	<1	1	<1		
Rash Erythematous	<1	1	<1		
Special Sense Other, Disorders					
Taste Perversion	0	2	4		
Urinary System Disorders					
Hematuria	1	2	<1		
Urinary Tract Infection	1	2	3		
Micturition Frequency	1	1	2		
Urinary Incontinence	<1	2	1		
Urine Abnormal	0	1	<1		
Vision Disorders					
Vision Abnormal	2	13	10		
Diplopia	5	10	10		
White Cell and RES Disorders					
Leukopenia	1	2	1		

^a Patients in these add-on trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to TOPAMAX[®] or placebo. ^b Values represent the percentage of patients reporting a given adverse event. Patients may have reported more than one

adverse event during the study and can be included in more than one adverse event category.

^c Adverse events reported by at least 1% of patients in the TOPAMAX[®] 200-400 mg/day group and more common than in the placebo group are listed in this table.

Incidence in Study 119 – Add-On Therapy– Adults with Partial Onset Seizures

Study 119 was a randomized, double-blind, placebo-controlled, parallel group study with 3 treatment arms: 1) placebo; 2) topiramate 200 mg/day with a 25 mg/day starting dose, increased by 25 mg/day each week for 8 weeks until the 200 mg/day maintenance dose was reached; and 3) topiramate 200 mg/day with a 50 mg/day starting dose, increased by 50 mg/day each week for 4 weeks until the 200 mg/day maintenance dose was reached. All patients were maintained on concomitant carbamazepine with or without another concomitant antiepileptic drug.

The incidence of adverse events (Table 7) did not differ significantly between the 2 topiramate regimens. Because the frequencies of adverse events reported in this study were markedly lower than those reported in the previous epilepsy studies, they cannot be directly compared with data obtained in other studies.

Tophaniae Group and Greater Than the Rate in T		TOPAMAX [®] Dosage
Body System/	Placebo	(mg/day) 200
Adverse Event ^c	(N=92)	(N=171)
Body as a Whole-General Disorders	(17.92)	
Fatigue	4	9
Chest Pain	1	2
Cardiovascular Disorders, General	1	2
Hypertension	0	2
Central & Peripheral Nervous System Disorders	0	2
Paresthesia	2	9
Dizziness	4	7
Tremor	2	3
Hypoasthesia	0	2
Leg Cramps	0	$\frac{2}{2}$
Language Problems	0	2
Gastro-Intestinal System Disorders	0	2
Abdominal Pain	3	5
Constipation	0	4
Diarrhea	1	2
Dyspepsia	0	$\frac{2}{2}$
Dyspepsia Dry Mouth	0	$\frac{2}{2}$
Hearing and Vestibular Disorders	0	2
Tinnitus	0	2
Metabolic and Nutritional Disorders	0	2
Weight Decrease	4	8
Psychiatric Disorders	4	8
Somnolence	9	15
Anorexia	7	9
Nervousness	2	9
Difficulty with Concentration/Attention	$\frac{2}{0}$	5
Insomnia	3	4
Difficulty with Memory	1	2
Aggressive Reaction	0	$\frac{2}{2}$
Respiratory System Disorders	0	2
Respiratory System Disorders Rhinitis	0	4
Urinary System Disorders	U	4
Cystitis	0	2
Vision Disorders	U	Z
	0	2
Diplopia Vision Abnormal	0	2
vision Autormai	U	2

Table 7:Incidence of Treatment-Emergent Adverse Events in Study $119^{a,b}$ Where Rate Was $\geq 2\%$ in the
Topiramate Group and Greater Than the Rate in Placebo-Treated Patients

^a Patients in these add-on trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to TOPAMAX[®] or placebo.
 ^b Values represent the percentage of patients reporting a given adverse event. Patients may have reported more than one

adverse event during the study and can be included in more than one adverse event category.

^c Adverse events reported by at least 2% of patients in the TOPAMAX[®] 200 mg/day group and more common than in the placebo group are listed in this table.

		TOPAMAX [®] Dosage (mg/day)		
	Placebo	200	400	600 - 1,000
Adverse Event	(N =216)	(N = 45)	(N = 68)	(N = 414)
Fatigue	13	11	12	30
Nervousness	7	13	18	19
Difficulty with Concentration/Attention	1	7	9	14
Confusion	4	9	10	14
Depression	6	9	7	13
Anorexia	4	4	6	12
Language problems	<1	2	9	10
Anxiety	6	2	3	10
Mood problems	2	0	6	9
Weight decrease	3	4	9	13

Table 8:Incidence (%) of Dose-Related Adverse Events From Placebo-Controlled, Add-On
Trials in Adults with Partial Onset Seizures^a

^a Dose-response studies were not conducted for other adult indications or for pediatric indications.

Body System/	Placebo	Topiramate
Adverse Event	(N=101)	(N=98)
Body as a Whole - General Disorders	-	
Fatigue	5	16
Injury	13	14
Allergic Reaction	1	2
Back Pain	0	1
Pallor	0	1
Cardiovascular Disorders, General	0	
Hypertension	0	1
Central & Peripheral Nervous System Disorders	-	0
Gait Abnormal	5	8
Ataxia	2	6
Hyperkinesia	4	5
Dizziness	2	4
Speech Disorders/Related Speech Problems	2	4
Hyporeflexia	0	2
Convulsions Grand Mal	0	1
Fecal Incontinence	0	1
Paresthesia	0	1
Gastro-Intestinal System Disorders		
Nausea	5	6
Saliva Increased	4	6
Constipation	4	5
Gastroenteritis	2	3
Dysphagia	0	1
Flatulence	0	1
Gastroesophageal Reflux	0	1
Glossitis	0	1
Gum Hyperplasia	0	1
Heart Rate and Rhythm Disorders		
Bradycardia	0	1
Metabolic and Nutritional Disorders		
Weight Decrease	1	9
Thirst	1	2
Hypoglycemia	0	1
Weight Increase	0	1
Platelet, Bleeding, & Clotting Disorders		
Purpura	4	8
Epistaxis	1	4
Hematoma	0	1
Prothrombin Increased	0	1
Thrombocytopenia	0	1
sychiatric Disorders		
Somnolence	16	26
Anorexia	15	24
Nervousness	7	14
Personality Disorder (Behavior Problems)	9	11
Difficulty with Concentration/Attention	2	10
Aggressive Reaction	4	9
Insomnia	7	8
Difficulty with Memory NOS	0	5
Confusion	3	4
Psychomotor Slowing	2	3
Appetite Increased	$\overline{0}$	1
Neurosis	0	1

Table 9: Incidence (%) of Treatment-Emergent Adverse Events in Placebo-Controlled, Add-On Epilepsy Trials

(Continued)

Patients and Occurred More Frequently in Topiramate-Treated Than Placebo-Treated Patients) (Continued) Body System/ Placebo Topiramate (N=101) (N=98) Adverse Event **Reproductive Disorders, Female** Leukorrhoea 0 2 **Resistance Mechanism Disorders** 3 7 Infection Viral **Respiratory System Disorders** 5 Pneumonia 1 Respiratory Disorder 0 1 Skin and Appendages Disorders 3 Skin Disorder 2 Alopecia 1 2 2 0 Dermatitis Hypertrichosis 2 1 Rash Erythematous 2 0 Eczema 0 1 Seborrhoea 0 1 Skin Discoloration 0 1 **Urinary System Disorders** Urinary Incontinence 2 4 0 Nocturia 1 **Vision Disorders** 2 Eye Abnormality 1 Vision Abnormal 1 2 Diplopia 0 1 0 Lacrimation Abnormal 1 Myopia 0 1 White Cell and RES Disorders Leukopenia 0

Table 9: Incidence (%) of Treatment-Emergent Adverse Events in Placebo-Controlled, Add-On Epilepsy Trials in Pediatric Patients Ages 2 -16 Years^{a,b} (Events that Occurred in at Least 1% of Topiramate-Treated

Patients in these add-on trials were receiving 1 to 2 concomitant antiepileptic drugs in addition to TOPAMAX[®] or placebo.

Values represent the percentage of patients reporting a given adverse event. Patients may have reported more than one adverse event during the study and can be included in more than one adverse event category.

Other Adverse Events Observed During All Epilepsy Clinical Trials

Topiramate has been administered to 2,246 adults and 427 pediatric patients with epilepsy during all clinical studies, only some of which were placebo controlled. During these studies, all adverse events were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using modified WHOART dictionary terminology. The frequencies presented represent the proportion of patients who experienced an event of the type cited on at least one occasion while receiving topiramate. Reported events are included except those already listed in the previous tables or text, those too general to be informative, and those not reasonably associated with the use of the drug.

Events are classified within body system categories and enumerated in order of decreasing frequency using the following definitions: *frequent* occurring in at least 1/100 patients; *infrequent* occurring in 1/100 to 1/1000 patients; *rare* occurring in fewer than 1/1000 patients.

Autonomic Nervous System Disorders: Infrequent: vasodilation.

Body as a Whole: *Frequent:* syncope. *Infrequent:* abdomen enlarged. *Rare:* alcohol intolerance.

Cardiovascular Disorders, General: *Infrequent:* hypotension, postural hypotension, angina pectoris.

Central & Peripheral Nervous System Disorders: *Infrequent:* neuropathy, apraxia, hyperaesthesia, dyskinesia, dysphonia, scotoma, ptosis, dystonia, visual field defect, encephalopathy, EEG abnormal. *Rare:* upper motor neuron lesion, cerebellar syndrome, tongue paralysis.

Gastrointestinal System Disorders: *Infrequent:* hemorrhoids, stomatitis, melena, gastritis, esophagitis. *Rare:* tongue edema.

Heart Rate and Rhythm Disorders: Infrequent: AV block.

Liver and Biliary System Disorders: Infrequent: SGPT increased, SGOT increased.

Metabolic and Nutritional Disorders: *Infrequent:* dehydration, hypokalemia, alkaline phosphatase increased, hypocalcemia, hyperlipemia, hyperglycemia, xerophthalmia, diabetes mellitus. *Rare:* hyperchloremia, hypernatremia, hyponatremia, hypocholesterolemia, hypophosphatemia, creatinine increased.

Musculoskeletal System Disorders: Frequent: Arthralgia. Infrequent: arthrosis.

Neoplasms: Infrequent: thrombocythemia. Rare: polycythemia.

Platelet, Bleeding, and Clotting Disorders: *Infrequent:* gingival bleeding, pulmonary embolism.

Psychiatric Disorders: *Frequent:* impotence, hallucination, psychosis, suicide attempt. *Infrequent:* euphoria, paranoid reaction, delusion, paranoia, delirium, abnormal dreaming. *Rare:* libido increased, manic reaction.

Red Blood Cell Disorders: *Frequent:* anemia. *Rare:* marrow depression, pancytopenia.

Reproductive Disorders, Male: Infrequent: ejaculation disorder, breast discharge.

Skin and Appendages Disorders: *Infrequent:* urticaria, photosensitivity reaction, abnormal hair texture. *Rare:* chloasma.

Special Senses Other, Disorders: Infrequent: taste loss, parosmia.

Urinary System Disorders: *Infrequent:* urinary retention, face edema, renal pain, albuminuria, polyuria, oliguria.

Vascular (Extracardiac) Disorders: *Infrequent:* flushing, deep vein thrombosis, phlebitis. *Rare:* vasospasm.

Vision Disorders: *Frequent:* conjunctivitis. *Infrequent:* abnormal accommodation, photophobia, strabismus. *Rare:* mydriasis, iritis.

WhiteCellandReticuloendothelialSystemDisorders:Infrequent:lymphadenopathy,eosinophilia,lymphopenia,granulocytopenia.Rare:lymphocytosis.

Migraine

In the four multicenter, randomized, double-blind, placebo-controlled, parallel group migraine prophylaxis clinical trials, most of the adverse events with topiramate were mild or moderate in severity. Most adverse events occurred more frequently during the titration period than during the maintenance period.

Table 10 includes those adverse events reported for patients in the placebo-controlled trials where the incidence rate in any topiramate treatment group was at least 2% and was greater than that for placebo patients.

Was ≥2 % in Any Topiramate Group and Greater than the Rate in Placebo-Treated Patients ^a TOPAMAX [®] Dosage (mg/day)				1
Body System/	Placebo	50	100	200
Adverse Event	(N=445)	(N=235)	(N=386)	(N=514)
Body as a Whole-General Disorders				
Fatigue	11	14	15	19
Injury	7	9	6	6
Asthenia	1	<1	2	2
Fever	1	1	1	2
Influenza-Like Symptoms	<1	<1	<1	2
Allergy	<1	2	<1	<1
Central & Peripheral Nervous System Disorders				
Paresthesia	6	35	51	49
Dizziness	10	8	9	12
Hypoaesthesia	2	6	7	8
Language Problems	2	7	6	7
Involuntary Muscle Contractions	1	2	2	4
Ataxia	<1	1	2	1
Speech Disorders/Related Speech Problems	<1	1	<1	2
Gastro-Intestinal System Disorders	~1	1	-1	2
Nausea	8	9	13	14
Diarrhea	4	9	13	14
Abdominal Pain	5	6	6	7
Dyspepsia	3	4	5	3
Dyspepsia Dry Mouth	2	4 2	3	5
Vomiting	2	2	3 2	3
e	2	3	2 3	3 2
Gastroenteritis	I	3	3	2
Hearing and Vestibular Disorders	1	.1		2
Tinnitus	1	<1	1	2
Metabolic and Nutritional Disorders		6	0	11
Weight Decrease	1	6	9	11
Thirst	<1	2	2	1
Musculoskeletal System Disorders		_		
Arthralgia	2	7	3	1
Neoplasms				
Neoplasm NOS	<1	2	<1	<1
Psychiatric Disorders				
Anorexia	6	9	15	14
Somnolence	5	8	7	10
Difficulty with Memory NOS	2	7	7	11
Difficulty with Concentration/Attention	2	3	6	10
Insomnia	5	6	7	6
Anxiety	3	4	5	6
Mood Problems	2	3	6	5
Depression	4	3	4	6
Nervousness	2	4	4	4
Confusion	2	2	3	4
Psychomotor Slowing	1	3	2	4
Libido Decreased	1	1	1	2
Aggravated Depression	1	1	2	2
Agitation	1	2	2	1
Cognitive Problems NOS	1	<1	2	2
Reproductive Disorders, Female	1	<u></u>	4	4
Menstrual Disorder	2	3	2	2
Reproductive Disorders, Male	2	3	2	2
1	0	2	0	0
Ejaculation Premature	0	3	0	0
Resistance Mechanism Disorders	2	4	4	2
Viral Infection	3	4	4	3
Otitis Media	<1	2	1	1
Respiratory System Disorders	10	10		10
Upper Respiratory Tract Infection	12	13	14	12
Sinusitis	6	10	6	8
Pharyngitis	4	5	6	2
Coughing	2	2	4	3

Table 10:Incidence of Treatment-Emergent Adverse Events in Placebo-Controlled, Migraine Trials Where Rate
Was ≥ 2 % in Any Topiramate Group and Greater than the Rate in Placebo-Treated Patients^a

Bronchitis	2	3	3	3
Dyspnea	2	1	3	2
Rhinitis	1	1	2	2
				(Continued)

Table 10:Incidence of Treatment-Emergent Adverse Events in Placebo-Controlled, Migraine Trials Where Rate
Was ≥ 2 % in Any Topiramate Group and Greater than the Rate in Placebo-Treated Patients ^a

	TOPAMAX [®] Dosage (mg/day)			
Body System/	Placebo	50	100	200
Adverse Event	(N=445)	(N=235)	(N=386)	(N=514)
Skin and Appendages Disorders				
Pruritis	2	4	2	2
Special Sense Other, Disorders				
Taste Perversion	1	15	8	12
Taste Loss	<1	1	1	2
Urinary System Disorders				
Urinary Tract Infection	2	4	2	4
Renal Calculus	0	0	1	2
Vision Disorders				
Vision Abnormal	<1	1	2	3
Blurred Vision ^b	2	4	2	4
Conjunctivitis	1	1	2	1

^a Values represent the percentage of patients reporting a given adverse event. Patients may have reported more than one adverse event during the study and can be included in more than one adverse event category.

^b Blurred vision was the most common term considered as vision abnormal. Blurred vision was an included term that accounted for > 50 % of events coded as vision abnormal, a preferred term.

Of the 1,135 patients exposed to topiramate in the placebo-controlled studies, 25% discontinued due to adverse events, compared to 10% of the 445 placebo patients. The adverse events associated with discontinuing therapy in the topiramate-treated patients included paresthesia (7%), fatigue (4%), nausea (4%), difficulty with concentration/attention (3%), insomnia (3%), anorexia (2%), and dizziness (2%).

Patients treated with topiramate experienced mean percent reductions in body weight that were dose-dependent. This change was not seen in the placebo group. Mean changes of 0%, -2%, -3%, and -4% were seen for the placebo group, topiramate 50, 100, and 200 mg groups, respectively.

Table 11 shows adverse events that were dose-dependent. Several central nervous system adverse events, including some that represented cognitive dysfunction, were dose-related. The most common dose-related adverse events were paresthesia, fatigue, nausea, anorexia, dizziness, difficulty with memory, diarrhea, weight decrease, difficulty with concentration/attention, and somnolence.

Table 11: Incidence (%) of I	Dose-Related Adv	erse Events From Pla		
	TOPAMAX [®] Dosage (mg/day)			osage (mg/day)
	Placebo	50	100	200
Adverse Event	(N =445)	(N = 235)	(N = 386)	(N = 514)
Paresthesia	6	35	51	49
Fatigue	11	14	15	19
Nausea	8	9	13	14
Anorexia	6	9	15	14
Dizziness	10	8	9	12
Weight decrease	1	6	9	11
Difficulty with Memory NOS	2	7	7	11
Diarrhea	4	9	11	11
Difficulty with	2	3	6	10
Concentration/Attention				
Somnolence	5	8	7	10
Hypoaesthesia	2	6	7	8
Anxiety	3	4	5	6
Depression	4	3	4	6
Mood Problems	2	3	6	5
Dry Mouth	2	2	3	5
Confusion	2	2	3	4
Involuntary Muscle	1	2	2	4
Contractions				
Abnormal Vision	<1	1	2	3
Renal Calculus	0	0	1	2

The incidence rate of the adverse event in the 200 mg/day group was $\geq 2\%$ than the rate in both the placebo group and the 50 mg/day group.

Other Adverse Events Observed During Migraine Clinical Trials

Topiramate, for the treatment of prophylaxis of migraine headache, has been administered to 1,367 patients in all clinical studies (includes double-blind and openlabel extension). During these studies, all adverse events were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using modified WHOART dictionary terminology.

The following additional adverse events that were not described earlier were reported by greater than 1% of the 1,367 topiramate-treated patients in the controlled clinical trials.

Body as a Whole: Pain, chest pain, allergic reaction.

Central & Peripheral Nervous System Disorders: Headache, vertigo, tremor, sensory disturbance, migraine aggravated.

Gastrointestinal System Disorders: Constipation, gastroesophageal reflux, tooth disorder

Musculoskeletal System Disorders: Myalgia.

Platelet, Bleeding, and Clotting Disorders: Epistaxis.

Reproductive Disorders, Female: Intermenstrual bleeding.

Resistance Mechanism Disorders: Infection, genital moniliasis.

Respiratory System Disorders: Pneumonia, asthma.

Skin and Appendages Disorders: Rash, alopecia.

Vision Disorders: Abnormal accommodation, eye pain.

Postmarketing and Other Experience

In addition to the adverse experiences reported during clinical testing of $TOPAMAX^{(R)}$, the following adverse experiences have been reported worldwide in patients receiving topiramate post-approval. These adverse experiences have not been listed above and data are insufficient to support an estimate of their incidence or to establish causation. The listing is alphabetized: bullous skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), hepatic failure (including fatalities), hepatitis, pancreatitis, pemphigus, and renal tubular acidosis.

DRUG ABUSE AND DEPENDENCE

The abuse and dependence potential of $\mathrm{TOPAMAX}^{\mathbb{R}}$ has not been evaluated in human studies.

OVERDOSAGE

Overdoses of TOPAMAX[®] have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbance, blurred vision, diplopia, mentation impaired, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after poly-drug overdoses involving TOPAMAX[®].

Topiramate overdose has resulted in severe metabolic acidosis (see WARNINGS).

A patient who ingested a dose between 96 and 110 g topiramate was admitted to hospital with coma lasting 20-24 hours followed by full recovery after 3 to 4 days.

In acute TOPAMAX[®] overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate *in vitro*. Treatment should be appropriately supportive. Hemodialysis is an effective means of removing topiramate from the body.

DOSAGE AND ADMINISTRATION Epilepsy

In the controlled add-on trials, no correlation has been demonstrated between trough plasma concentrations of topiramate and clinical efficacy. No evidence of tolerance has been demonstrated in humans. Doses above 400 mg/day (600, 800, or 1000 mg/day) have not been shown to improve responses in dose-response studies in adults with partial onset seizures.

It is not necessary to monitor topiramate plasma concentrations to optimize TOPAMAX[®] therapy. On occasion, the addition of TOPAMAX[®] to phenytoin may require an adjustment of the dose of phenytoin to achieve optimal clinical outcome. Addition or withdrawal of phenytoin and/or carbamazepine during adjunctive therapy with TOPAMAX[®] may require adjustment of the dose of TOPAMAX[®]. Because of the bitter taste, tablets should not be broken.

 $TOPAMAX^{\mathbb{R}}$ can be taken without regard to meals.

Monotherapy Use

The recommended dose for topiramate monotherapy in adults and children 10 years of age and older is 400 mg/day in two divided doses. Approximately 58% of patients randomized to 400 mg/day achieved this maximal dose in the monotherapy controlled trial; the mean dose achieved in the trial was 275 mg/day. The dose should be achieved by titrating according to the following schedule:

	Morning Dose	Evening Dose
Week 1	25 mg	25 mg
Week 2	50 mg	50 mg
Week 3	75 mg	75 mg
Week 4	100 mg	100 mg
Week 5	150 mg	150 mg
Week 6	200 mg	200 mg

Adjunctive Therapy Use Adults (17 Years of Age and Over) - Partial Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome

The recommended total daily dose of TOPAMAX[®] as adjunctive therapy in adults with partial seizures is 200-400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. It is recommended that therapy be initiated at 25-50 mg/day followed by titration to an effective dose in increments of 25-50 mg/week. Titrating in increments of 25 mg/week may delay the time to reach an effective dose. Daily doses above 1,600 mg have not been studied.

In the study of primary generalized tonic-clonic seizures the initial titration rate was slower than in previous studies; the assigned dose was reached at the end of 8 weeks (see CLINICAL STUDIES, Adjunctive Therapy Controlled Trials in Patients With Primary Generalized Tonic-Clonic Seizures).

Pediatric Patients (Ages 2 - 16 Years) - Partial Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome

The recommended total daily dose of TOPAMAX[®] (topiramate) as adjunctive therapy for patients with partial seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut Syndrome is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome.

In the study of primary generalized tonic-clonic seizures the initial titration rate was slower than in previous studies; the assigned dose of 6 mg/kg/day was reached at the end of 8 weeks (see CLINICAL STUDIES, Adjunctive Therapy Controlled Trial in Patients With Primary Generalized Tonic-Clonic Seizures).

Migraine

The recommended total daily dose of TOPAMAX[®] as treatment for prophylaxis of migraine headache is 100 mg/day administered in two divided doses. The recommended titration rate for topiramate for migraine prophylaxis to 100 mg/day is:

	Morning Dose	Evening Dose
Week 1	None	25 mg
Week 2	25 mg	25 mg
Week 3	25 mg	50 mg
Week 4	50 mg	50 mg

Dose and titration rate should be guided by clinical outcome. If required, longer intervals between dose adjustments can be used.

Administration of TOPAMAX[®] Sprinkle Capsules

TOPAMAX[®] (topiramate capsules) Sprinkle Capsules may be swallowed whole or may be administered by carefully opening the capsule and sprinkling the entire contents on a small amount (teaspoon) of soft food. This drug/food mixture should be swallowed immediately and not chewed. It should not be stored for future use.

Patients with Renal Impairment:

In renally impaired subjects (creatinine clearance less than $70 \text{ mL/min/}1.73\text{m}^2$), one half of the usual adult dose is recommended. Such patients will require a longer time to reach steady-state at each dose.

Geriatric Patients (Ages 65 Years and Over):

Dosage adjustment may be indicated in the elderly patient when impaired renal function (creatinine clearance rate \leq 70 mL/min/1.73 m²) is evident (see DOSAGE AND ADMINISTRATION: Patients with Renal Impairment and CLINICAL PHARMACOLOGY: Special Populations: Age, Gender, and Race).

Patients Undergoing Hemodialysis:

Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to fall below that required to maintain an anti-seizure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of topiramate in the patient being dialyzed.

Patients with Hepatic Disease:

In hepatically impaired patients topiramate plasma concentrations may be increased. The mechanism is not well understood.

HOW SUPPLIED

TOPAMAX[®] (topiramate) Tablets are available as debossed, coated, round tablets in the following strengths and colors:

25 mg white (coded "TOP" on one side; "25" on the other)50 mg light-yellow (coded "TOPAMAX" on one side; "50" on the other)

100 mg yellow (coded "TOPAMAX" on one side; "100" on the other) 200 mg salmon (coded "TOPAMAX" on one side; "200" on the other)

They are supplied as follows:

25 mg tablets – bottles of 60 count with desiccant (NDC 0045-0639-65) 50 mg tablets – bottles of 60 count with desiccant (NDC 0045-0640-65) 100 mg tablets – bottles of 60 count with desiccant (NDC 0045-0641-65) 200 mg tablets – bottles of 60 count with desiccant (NDC 0045-0642-65)

TOPAMAX[®] (topiramate capsules) Sprinkle Capsules contain small, white to off white spheres. The gelatin capsules are white and clear.

They are marked as follows: 15 mg capsule with "TOP" and "15 mg" on the side 25 mg capsule with "TOP" and "25 mg" on the side

The capsules are supplied as follows: 15 mg capsules – bottles of 60 (NDC 0045-0647-65) 25 mg capsules – bottles of 60 (NDC 0045-0645-65)

TOPAMAX[®] (topiramate) Tablets should be stored in tightly-closed containers at controlled room temperature (59 to 86°F, 15 to 30°C). Protect from moisture.

TOPAMAX[®] (topiramate capsules) Sprinkle Capsules should be stored in tightlyclosed containers at or below 25°C (77°F). Protect from moisture.

TOPAMAX[®] (topiramate) and TOPAMAX[®] (topiramate capsules) are trademarks of Ortho-McNeil Pharmaceutical.

HOW TO TAKE TOPAMAX[®] (topiramate capsules) SPRINKLE CAPSULES

A Guide for Patients and Their Caregivers

oatmeal, pudding, or yogurt.

Your doctor has given you a prescription for TOPAMAX[®] (topiramate capsules) Sprinkle Capsules. Here are your instructions for taking this medication. Please read these instructions prior to use.



To Take With Food You may sprinkle the contents of TOPAMAX[®] Sprinkle Capsules on a small amount (teaspoon) of soft food, such as applesauce, custard, ice cream,





Hold the capsule upright so that you can read the word "TOP".



Carefully twist off the clear portion of the capsule. You may find it best to do this over the small portion of the food onto which you will be pouring the sprinkles.



Sprinkle <u>all</u> of the capsule's contents onto a spoonful of soft food, taking care to see that the entire prescribed dosage is sprinkled onto the food.



Be sure the patient swallows the entire spoonful of the sprinkle/food mixture immediately. Chewing should be avoided. It may be helpful to have the patient drink fluids immediately in order to make sure all of the mixture is swallowed. IMPORTANT: Never store any sprinkle/food mixture for use at a later time.

To Take Without Food TOPAMAX[®] Sprinkle Capsules may also be swallowed as whole capsules

For more information about TOPAMAX[®] Sprinkle Capsules, ask your doctor or pharmacist.

OMP Division ORTHO-McNEIL PHARMACEUTICAL, INC. Raritan, New Jersey 08869